CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 17 enrolled
Drug / intervention
Radiofrequency ablation (RFA)device
Likely dose
NEUROMARK device radiofrequency ablation (in-office, disposable bipolar RFA with micro electrodes)AI-extracted
Key inclusion· 3
  • Chronic rhinitis symptoms (rhinorrhea, congestion, post-nasal drip) for at least 6 months
  • Poor response to medical management attempted for at least 4 weeks
  • rTNSS score ≥6 with rhinorrhea ≥2 and congestion ≥1
Key exclusion· 4
  • Active sinusitis
  • Rhinitis medicamentosa (medication-induced rhinitis)
  • Recurrent and ongoing epistaxis (nosebleeds)
  • Immunodeficiency or history of sinus surgery

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05648565
NCT05648565N/ACompleted

Effects of Radiofrequency Ablation of Posterior Nasal Nerves on Inflammatory Cytokines, Peak Nasal Inspiratory Flow, and Nasal Blood Flow in Patients With Chronic Rhinitis

The University of Texas Health Science Center, Houston·interventional·Posted Dec 13, 2022·Updated Apr 3, 2025

In Brief

A clinical study evaluating Radiofrequency ablation (RFA) for Chronic Rhinitis. Completed, enrolled 17 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the effectiveness of radiofrequency ablation (RFA) of the posterior nasal nerve (PNN) in chronic rhinitis (CR) patients by comparing patient reflective total nasal symptom score (rTNSS) and nasal obstruction symptom evaluation (NOSE) , peak nasal inspiratory flow (PNIF) , and levels of Type 2 cytokines pre- and post-procedure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
2023202420252026
First PostedDec 13, 2022
Enrollment StartJan 10, 2023
Primary CompletionFeb 20, 2024
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 3.6 years ago

Interventions

Radiofrequency ablation (RFA)device

The NEUROMARK device is an in-office, disposable bipolar RFA device with a treatment tip consisting of micro electrodes which delivers RF energy while monitoring appropriate tissue contact to maximize delivery to posterior nasal nerve and its variable branching. After topical anesthesia consisting of oxymetazoline and 1% lido followed by 4% lidocaine, the device will be placed in the posterior inferior turbinate under endoscopic visualization. The device will be activated per manufacturer's instructions